Generic drug-maker stocks are collapsing following headlines suggesting the Justice Department’s probe into collusion and drastic price increases will see the first charges brought by year-end.
As Bloomberg reports, U.S. prosecutors are bearing down on generic pharmaceutical companies in a sweeping criminal investigation into suspected price collusion, a fresh challenge for an industry that’s already reeling from public outrage over the spiraling costs of some medicines.